Clinical TrialsCYB003's 71% remission rate at 12 months following two 16 mg doses, coupled with its FDA Breakthrough Therapy Designation, underscore meaningful registration potential.
Financial ResourcesThe recent announcement of a US$500 million convertible debenture facility—with US$50 million now funded—provides additional capital flexibility and extends runway beyond 2026.
Strategic PartnershipsCybin has expanded its partnership with Thermo Fisher Scientific to include U.S.-based manufacturing of both CYB003 drug substance and capsules, supporting Phase 3 supply and future commercial scale-up.